Valuation: Cell Source, Inc.

Market Cap 2.44Cr 2.15Cr 2.04Cr 1.85Cr 3.46Cr 234.27Cr 3.5Cr 24Cr 9.39Cr 119.6Cr 9.17Cr 8.97Cr 384.07Cr P/E 2023
-2.65x
P/E 2024 -2.49x
Enterprise Value 3.49Cr 3.08Cr 2.91Cr 2.64Cr 4.96Cr 335.11Cr 5Cr 35Cr 13Cr 171.09Cr 13Cr 13Cr 549.41Cr EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
80.32%
Yield 2023 *
-
Yield 2024 -
1 day-8.53%
1 week-13.55%
Current month-55.05%
1 month-30.92%
3 months-51.22%
6 months-44.20%
Current year-20.00%
1 week 0.36
Extreme 0.36
0.82
1 month 0.36
Extreme 0.36
0.89
Current year 0.25
Extreme 0.25
2.25
1 year 0.25
Extreme 0.25
2.25
3 years 0
Extreme 0.0002
2.25
5 years 0
Extreme 0.0002
2.25
10 years 0
Extreme 0
2.55
Manager TitleAgeSince
Chief Executive Officer 66 30/06/2014
Director TitleAgeSince
Chairman 77 18/05/2015
Director/Board Member 82 25/03/2021
Director/Board Member 72 10/03/2022
Date Insider Type Main position Quantity % Market Cap. Importance
09/08/21 Others

Director

8,00,000 2.4492%
30/06/21 Others

Director

4,860 0.0149%
30/06/21 Others

Chairman

2,976 0.0091%
Change 5-day change 1-year change 3-year change Capi.($)
+2.50%-13.55%-4.31%-41.18% 2.97Cr
-0.70%-4.35%+56.10%+86.42% 7.18TCr
+0.45%-2.26%+38.36%+87.74% 6.01TCr
+0.19%+0.94%+36.97%+21.32% 2.79TCr
-1.73%-4.44%-15.62%+348.87% 2.57TCr
-0.51%+0.58%+0.50%-3.39% 2.49TCr
+0.65%+2.52%+25.89%-6.99% 2.09TCr
+3.46%+3.91%+158.90%+337.81% 1.5TCr
+0.48%+2.50%+50.23%+161.95% 1.45TCr
+3.91%-4.56%-2.71%+506.41% 1.39TCr
Average -0.23%-0.81%+34.43%+149.90% 2.75TCr
Weighted average by Cap. +0.19%-0.49%+38.57%+128.32%

Financials

2023 2024
Net sales - -
Net income -53.21L -46.93L -44.39L -40.23L -75.51L -51Cr -76.19L -5.31Cr -2.05Cr -26Cr -2Cr -1.95Cr -84Cr -45.13L -39.8L -37.65L -34.12L -64.04L -43Cr -64.62L -4.5Cr -1.74Cr -22Cr -1.69Cr -1.66Cr -71Cr
Net Debt 92.74L 81.79L 77.37L 70.12L 1.32Cr 89Cr 1.33Cr 9.25Cr 3.57Cr 45Cr 3.48Cr 3.41Cr 145.92Cr 1.05Cr 92.67L 87.67L 79.45L 1.49Cr 100.85Cr 1.5Cr 10Cr 4.04Cr 51Cr 3.95Cr 3.86Cr 165.33Cr
Logo Cell Source, Inc.
Cell Source, Inc. is a cell therapy company focused on immunotherapy. The Company is primarily focused on the development of immune system management technology (Veto Cell technology). Its lead prospective product is its Veto Cell immune system management technology. Its Veto Cell technology is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is in pre-clinical phase, and its data shows that it provides results in allogeneic (donor-derived) hematopoietic stem cell transplantation (HSCT) by allowing for haploidentical stem cell transplants under a mild conditioning regimen. Its product pipeline includes chimeric antigen receptor (CAR) T-cell therapies, which include VETO CAR-T (with or without HSCT) for B-cell malignancies, Veto Cell kidney transplants, VETO CAR-T for solid tumors, Veto Cell liver transplants, and Veto HSCT for non-malignant disorders. The Company's wholly owned subsidiary is Cell Source Limited (CSL).
Employees
-
Date Price Change Volume
29/26/29 $0.4000 -8.53% 11,600
28/26/28 $0.4373 +4.25% 575
25/26/25 $0.4195 -9.19% 3,320
24/26/24 $0.4619 +2.97% 1,150
23/26/23 $0.4486 -2.18% 980
  1. Stock Market
  2. Stocks
  3. CLCS Stock